StonvexLoading…
StonvexStonvexStonvexCore line items from NOVT's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q2 2026 2026-04-03 | Annual 2025 2025-12-31 | Q3 2025 2025-09-26 | Q2 2025 2025-06-27 |
|---|---|---|---|---|
Revenue | $257.71M | $980.60M | $722.25M | $474.42M |
Operating Income | $27.54M | $94.01M | $69.18M | $47.33M |
Net Income | $21.10M | $53.83M | $36.36M | $25.70M |
EPS (Diluted) | $0.51 | $1.47 | $1.01 | $0.71 |
Total Assets | $1.80B | $1.81B | $1.51B | $1.51B |
Total Liabilities | $488.03M | $492.82M | $704.34M | $709.62M |
Cash & Equivalents | $388.80M | $380.87M | $89.22M | $109.91M |
Free Cash Flow OCF − CapEx | $47.47M | $48.43M | $43.30M | $39.08M |
Shares Outstanding | 35.61M | 35.67M | 35.85M | 35.97M |